Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ICAM1 | P05362 | 12/20 | 0.67 |
| ▸ | SELE | P16581 | 11/20 | 0.67 |
| ▸ | VCAM1 | P19320 | 5/20 | 0.67 |
| ▸ | PIM1 | P11309 | 7/20 | 0.63 |
| ▸ | GSK3A | P49840 | 7/20 | 0.63 |
| ▸ | GSK3B | P49841 | 7/20 | 0.63 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.63 |
| ▸ | PRKACA | P17612 | 6/20 | 0.63 |
| ▸ | RPS6KA3 | P51812 | 5/20 | 0.63 |
| ▸ | DAPK3 | O43293 | 5/20 | 0.63 |
| ▸ | KDR | P35968 | 5/20 | 0.63 |
| ▸ | MAPK8 | P45983 | 5/20 | 0.63 |
| ▸ | LIMK1 | P53667 | 5/20 | 0.63 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.63 |
| ▸ | FLT1 | P17948 | 3/20 | 0.63 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.63 |
| ▸ | CLK2 | P49760 | 3/20 | 0.63 |
| ▸ | MAP4K2 | Q12851 | 3/20 | 0.63 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.63 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30568694 | 1.00 | ICAM1 (0.67) | ICAM1SELEVCAM1PIM1GSK3A | |
| SCHEMBL15910879 | 0.85 | PIM1 (0.59) | ICAM1SELEVCAM1PIM1GSK3A | |
| SCHEMBL18105584 | 0.83 | ICAM1 (0.53) | ICAM1SELEVCAM1PIM1GSK3A | |
| SCHEMBL29069393 | 0.81 | ICAM1 (0.69) | ICAM1SELEVCAM1PIM1GSK3A | |
| SCHEMBL7054697 | 0.80 | ICAM1 (1.00) | ICAM1SELEVCAM1PIM1GSK3A | |
| SCHEMBL14023789 | 0.80 | ICAM1 (0.67) | ICAM1SELEVCAM1PIM1GSK3A | |
| SCHEMBL15518133 | 0.80 | ICAM1 (0.67) | ICAM1SELEVCAM1PIM1GSK3A | |
| SCHEMBL29831616 | 0.80 | ICAM1 (0.56) | ICAM1SELEVCAM1PIM1GSK3A | |
| SCHEMBL5550652 | 0.80 | ICAM1 (0.56) | ICAM1SELEVCAM1PIM1GSK3A | |
| SCHEMBL20278452 | 0.80 | CDK8 (0.55) | ICAM1SELEVCAM1PIM1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | STEWART ANDREW O (US) | 2003-11-27 | — | — | US | claimed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | claimed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | claimed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | claimed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | claimed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | claimed |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | CIT THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | CIT THERAPEUTICS LLC | 2024-10-31 | — | — | US | disclosed |
| CN-116730995-B | Hydrazide compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4373825-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2024-05-29 | — | — | EP | disclosed |
| CN-116730995-A | Hydrazide compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| WO-2023004376-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | Suvalent Therapeutics, Inc. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-2596793-B1 | Quinoline derivatives as PI3 kinase inhibitors | GLAXOSMITHKLINE LLC (US) | 2015-07-08 | — | — | EP | disclosed |
| US-6579882-B2 | Thieno(2,3-d)pyrimidine derivatives | ABBOTT LABORATORIES | 2003-06-17 | — | — | US | disclosed |
| EP-1181296-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2002-02-27 | — | — | EP | disclosed |
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ABBVIE INC. | 2001-09-06 | — | — | US | disclosed |
| US-6232320-B1 | THIENO(2,3-C)PYRIDINE AND 5H-THIENO(2,3-C)PYRAN DERIATIVES | ABBOTT LABORATORIES | 2001-05-15 | — | — | US | disclosed |
| EP-1090009-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000075145-A1 | CELL ADHESION-INHIBITING ANTIINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-1999062908-A2 | CELL ADHESION-INHIBITING ANTINFLAMMATORY COMPOUNDS | ABBOTT LABORATORIES (US) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010020030-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | ICAM1 1/4885SELE 16/4885VCAM1 2/4885 |
| US-20240360148-A1 | NITRILE SUMO INHIBITORS AND USES THEREOF | SUMO1, SUMO3, SUMO2 | ICAM1 1326/4885SELE 2792/4885VCAM1 2451/4885 |
| US-12612414-B2 | Nitrile SUMO inhibitors and uses thereof | SUMO1, SUMO3, PSMB6 | ICAM1 2789/4885SELE 4424/4885VCAM1 2470/4885 |
| US-20030220365-A1 | Cell adhesion-inhibiting antiinflammatory compounds | ICAM1, VCAM1, EPCAM | ICAM1 1/4885SELE 16/4885VCAM1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.